211 related articles for article (PubMed ID: 22150825)
41. Effectiveness of adaptive designs for phase II cancer trials.
López MF; Dupuy JF; Gonzalez CV
Contemp Clin Trials; 2012 Jan; 33(1):223-7. PubMed ID: 22001360
[TBL] [Abstract][Full Text] [Related]
42. Five-year change in statistical designs of phase II trials published in leading cancer journals.
Thezenas S; Duffour J; Culine S; Kramar A
Eur J Cancer; 2004 May; 40(8):1244-9. PubMed ID: 15110889
[TBL] [Abstract][Full Text] [Related]
43. Curtailed two-stage designs with two dependent binary endpoints.
Chen CM; Chi Y
Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
[TBL] [Abstract][Full Text] [Related]
44. Optimal dose-finding designs with correlated continuous and discrete responses.
Fedorov V; Wu Y; Zhang R
Stat Med; 2012 Feb; 31(3):217-34. PubMed ID: 22162014
[TBL] [Abstract][Full Text] [Related]
45. Multinomial phase II cancer trials incorporating response and early progression.
Zee B; Melnychuk D; Dancey J; Eisenhauer E
J Biopharm Stat; 1999 May; 9(2):351-63. PubMed ID: 10379698
[TBL] [Abstract][Full Text] [Related]
46. Parameter estimation following an adaptive treatment selection trial design.
Luo X; Wu SS; Xiong J
Biom J; 2010 Dec; 52(6):823-35. PubMed ID: 21154898
[TBL] [Abstract][Full Text] [Related]
47. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
[TBL] [Abstract][Full Text] [Related]
48. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
Ratain MJ; Karrison TG
Clin Cancer Res; 2007 Feb; 13(3):781-2. PubMed ID: 17289865
[No Abstract] [Full Text] [Related]
49. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
Kelly PJ; Stallard N; Todd S
J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
[TBL] [Abstract][Full Text] [Related]
50. Bivariate sequential designs for phase II trials.
Conaway MR; Petroni GR
Biometrics; 1995 Jun; 51(2):656-64. PubMed ID: 7662852
[TBL] [Abstract][Full Text] [Related]
51. One- and two-stage designs for stratified phase II clinical trials.
London WB; Chang MN
Stat Med; 2005 Sep; 24(17):2597-611. PubMed ID: 16118809
[TBL] [Abstract][Full Text] [Related]
52. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
53. Optimal adaptive two-stage designs for early phase II clinical trials.
Shan G; Wilding GE; Hutson AD; Gerstenberger S
Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
[TBL] [Abstract][Full Text] [Related]
54. One-sample proportion testing procedures for hypothesis of inequality.
Zhong W; Zhong B
J Biopharm Stat; 2013 May; 23(3):604-17. PubMed ID: 23611198
[TBL] [Abstract][Full Text] [Related]
55. Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.
Ivanova A; Paul B; Marchenko O; Song G; Patel N; Moschos SJ
J Biopharm Stat; 2016; 26(1):141-9. PubMed ID: 26368744
[TBL] [Abstract][Full Text] [Related]
56. Time-to-event analysis with treatment arm selection at interim.
Di Scala L; Glimm E
Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
[TBL] [Abstract][Full Text] [Related]
57. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
58. Trial design for evaluation of novel targeted therapies.
Farley J; Rose PG
Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
[TBL] [Abstract][Full Text] [Related]
59. A discrete-continuous mixture quantile function estimator with a practical application to phase II cancer clinical trials.
Hutson AD
Stat Med; 2008 May; 27(12):2094-109. PubMed ID: 18038447
[TBL] [Abstract][Full Text] [Related]
60. Two-stage designs for phase II cancer trials with ordinal responses.
Stallard N; Cockey L
Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
